Nanox Imaging's subsidiary USARAD is deepening its collaboration with AZmed to integrate AZmed's FDA-cleared X-ray AI suite into USARAD's radiology workflows via Nanox Marketplace. This AI technology assists radiologists in prioritizing and interpreting musculoskeletal and chest X-rays more efficiently, covering multiple FDA-cleared diagnostic areas such as fractures and lung conditions. The integration aims to streamline study routing and results delivery within USARAD’s cloud platform, enhancing diagnostic speed and accuracy across its U.S. radiologist network. This move supports Nanox's broader goal of advancing preventive healthcare through innovative imaging and AI solutions.
USARAD, a Nanox Company, expanding its AI collaboration with AZmed, is presented here with Health-sector market data from Pluang as of Nov 09, 2026 20:42 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 110 rose and 27 fell today. Notable movers include Immunovant Inc. (IMVT) up 10.51% at USD 33.74 with a typical hold time of 17 days, Inovio Pharmaceuticals Inc. (INO) up 9.47% at USD 1.33 with a typical hold time of 41 days, and Arrowhead Pharmaceuticals Inc. (ARWR) down 7.59% at USD 53.74 with a typical hold time of 24 days.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
